Skip to main content
main-content

30.06.2016 | Chemotherapie | Onlineartikel

New approaches are raising hope for SCLC patients

Figure 1: Superiority of nivolumab-1/ipilimumab-3 for overall survival in patients with recurrent SCLC, as compared to nivolumab-3/ipilimumab-1 and nivolumab monotherapy

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weiterführende Themen